Allosteric Inhibition of the Hepatitis C Virus NS5B RNA Dependent RNA Polymerase

Author(s): Uwe Koch, Frank Narjes.

Journal Name: Infectious Disorders - Drug Targets
(Formerly Current Drug Targets - Infectious Disorders)

Volume 6 , Issue 1 , 2006

Become EABM
Become Reviewer


The human and monetary costs of chronic hepatitis C and the complications arising from this disease emphasize the urgency to find a treatment for Hepatitis C Virus (HCV) infected patients. The current standard of treatment for patients chronically infected with HCV is combination therapy with pegylated interferon plus ribavirin. Recently, viral enzymes have become the target of efforts to develop small molecule inhibitors interfering with the essential steps in the life cycle of the virus. Amongst these enzymes the HCV-encoded NS5B RNA-dependent RNA polymerase (NS5B RdRp) is essential for viral replication and has been recognized as a prime target for therapeutic intervention. Several distinct classes of inhibitors of NS5B RdRp have been disclosed in the literature, including active site inhibitors such as nucleosides and pyrophosphate mimetics, as well as non-nucleoside inhibitors. The latter, based on the success of allosteric inhibitors in the treatment of HIV infection, have been developed into compounds which show activity in the subgenomic cell-culture assay of HCV replication. This review provides an account of the recent developments in this field.

Keywords: Allosteric inhibition, Hepatitis C virus, RNA polymerase, sub-genomic replicon

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [31 - 41]
Pages: 11
DOI: 10.2174/187152606776056724

Article Metrics

PDF: 20